Kliniske studier for KOLS i Oklahoma
8 studier for KOLS søker deltakere på steder i Oklahoma.
Byer i Oklahoma
Offisiell studietekst (engelsk)
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
- Research Site, Norman
- Research Site, Oklahoma City
- Research Site, Tulsa
RekruttererFase 3
Alder 40 til 80 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06283966Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- Layrek Clinical Research- Site Number : 8400066, Tulsa
RekruttererFase 3
Alder 40 til 80 · Alle kjønn · Oppdatert 1. okt. 2026 · NCT07190222Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
- Epic Medical Research - Chickasha- Site Number : 8400097, Chickasha
RekruttererFase 3
Alder 40 til 80 · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07190209A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
- Research Site, Oklahoma City
- Research Site, Tulsa
RekruttererFase 2
Alder 40 og eldre · Alle kjønn · Oppdatert 9. sep. 2026 · NCT07082738A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
- Research Site, Oklahoma City
- Research Site, Tulsa
RekruttererFase 3
Alder 40 til 80 · Alle kjønn · Oppdatert 3. sep. 2026 · NCT06878261A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
- Research Site, Oklahoma City
RekruttererFase 3
Alder 40 til 80 · Alle kjønn · Oppdatert 3. sep. 2026 · NCT06883305eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
- GSK Investigational Site, Edmond
RekruttererFase 3
Alder 40 til 75 · Alle kjønn · Oppdatert 28. jul. 2026 · NCT07177339Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
- Hightower Clinical, Oklahoma City
RekruttererObservasjonsstudie
Alder 50 og eldre · Alle kjønn · Oppdatert 5. aug. 2025 · NCT06122077Fra ClinicalTrials.gov, data hentet 4. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.